Cargando…
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
BACKGROUND: Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease (COPD). METHODS: This was a multicentre, randomised, double-blind, placebo-controlled, three-way cross-over, incomplete block study to evaluate UMEC 15.6,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029330/ https://www.ncbi.nlm.nih.gov/pubmed/24393134 http://dx.doi.org/10.1186/1471-2466-14-2 |